Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02539459|
Recruitment Status : Terminated (Extreme toxicity, met toxicity stopping rules)
First Posted : September 3, 2015
Results First Posted : February 17, 2021
Last Update Posted : December 15, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Sporadic Angiomyolipomas (AMLs)||Drug: Everolimus||Phase 2|
1. To evaluate the efficacy and tolerability of everolimus in reducing tumor volume in sporadic AMLs as measured by dynamic contrast enhanced magnetic resonance imaging (DCE MRI), in patients who might otherwise be considered for active surgical or percutaneous intervention.
- To evaluate health-related quality of life (HRQoL) in subjects treated with everolimus for sporadic AMLs.
- To assess the growth kinetics of sporadic AMLs in patients who have been treated with everolimus as part of the study and demonstrate an objective response as well as those who have been treated with everolimus during the study with a suboptimal or no response.
- To measure the rate of surgical or percutaneous (embolization) intervention at 1 year from day 1 of study.
- To assess the safety and tolerability of everolimus in patients with sporadic AML.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy|
|Actual Study Start Date :||September 23, 2015|
|Actual Primary Completion Date :||August 20, 2018|
|Actual Study Completion Date :||August 20, 2018|
Experimental: Treatment (everolimus)
Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
10 mg tablets
- Number of Patients With Tumor Volume Reduction Greater Than 25% [ Time Frame: 12 months ]Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI
- Safety and Tolerability of Everolimus in Patients With Sporadic AML [ Time Frame: 12 months ]Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Must have a diagnosis of renal AML > 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI)
- Must not have received any prior treatment for AML
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Absolute neutrophil count >= 1,500/ microliter (mcL)
- Hemoglobin >=10 g/dL
- Platelets >= 100,000/ mcL
- international normalized ratio (INR) <= 1.2 X Upper limit Normal (ULN)
- activated partial thromboplastin time (aPTT) <= 1.2 X ULN
- aspartate aminotransferase (AST) / alanine transaminase (ALT) <= 2.5 X ULN
- Total bilirubin <= 2.0mg/dL
- Renal Function epidermal growth factor receptor (eGFR) >= 30 mL/min via calculated creatinine clearance
- Fasting serum cholesterol <= 300 mg/dL OR <= 7.75 mmol/L AND fasting triglycerides <= 2.5x ULN.
- History of tuberous sclerosis, LAM or any active malignancy
- Treatment with any other investigational agents for any other disease
- Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product
- Active diarrhea of any grade.
- History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection
- Presence of any active or ongoing infection.
- Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs)
- History of certain cardiovascular conditions within the past 6 months
- History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure.
- History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- Corrected QT interval (QTc) > 480 milliseconds
- Poorly controlled hypertension, defined as systolic blood pressure (SBP) of >= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of >= 90 mmHg.
- Evidence of active bleeding or bleeding diathesis
- Uncontrolled diabetes mellitus (defined by a Hgb A1c >8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c <= 8) must be achieved before registration and monitored during protocol treatment
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
- Unable or unwilling to discontinue use of prohibited medications
- Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug.
- Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus
- Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2).
- Pregnant or nursing (lactating) women
- Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after.
- Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR <30.
- Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment
- Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization.
- History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for >= 3 years
- Childs-Pugh A-C liver disease (Appendix II)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02539459
|United States, Connecticut|
|Yale School of Medicine|
|New Haven, Connecticut, United States|
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States|
|United States, Minnesota|
|Rochester, Minnesota, United States|
|United States, New York|
|Memorial Sloan Kettering|
|New York, New York, United States|
|United States, North Carolina|
|Duke University Health System|
|Durham, North Carolina, United States|
|United States, Pennsylvania|
|Fox Chase Cancer Center|
|Philadelphia, Pennsylvania, United States, 19111|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States|
|United States, Texas|
|M D Anderson Cancer Center|
|Houston, Texas, United States|
|Principal Investigator:||Robert G Uzzo, MD||PI|
Documents provided by Fox Chase Cancer Center:
|Responsible Party:||Fox Chase Cancer Center|
|Other Study ID Numbers:||
|First Posted:||September 3, 2015 Key Record Dates|
|Results First Posted:||February 17, 2021|
|Last Update Posted:||December 15, 2022|
|Last Verified:||December 2022|
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Physiological Effects of Drugs